Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

8.380 +0.660 (+8.55%)
Streaming Delayed Price Updated: 11:59 AM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent Biosolutions

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
After Trump's Win, It's Time To Take Profits On Gold
Via Benzinga
Topics Government
Exposures Political
Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise
The U.S. overdose crisis and its racial disparities were overlooked in the election, as Black and Indigenous Americans face rising death rates. 
Via Benzinga
Topics Death
Exposures Death
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
Emergent BioSolutions stock rises on mixed Q3 results, improved 2024 guidance, and news of a new trial for mpox treatment in Africa led by the CDC. 
Via Benzinga
Crude Oil Rises 1%; US Jobless Claims Increase To 221,000
Via Benzinga
Exposures Fossil Fuels
Gold Gains 1%; Halliburton Posts Weak Q3 Results
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday
Via Benzinga
The Post-Trump Victory Trade
The Trump Trade. 
Via Benzinga
Topics Government
Exposures Political
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript
EBS earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
From Emergent BioSolutions
Via GlobeNewswire
What's Going On With Emergent BioSolutions Stock Wednesday?
Emergent BioSolutions stock is trading higher after the company announced the closing of a $100 million asset-backed revolving loan facility. 
Via Benzinga
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines
Emergent BioSolutions secures $400M in orders for smallpox and mpox products, receives FDA approval for ACAM2000's expanded use, and updates its 2024 revenue forecast while beating Q2 sales estimates. 
Via Benzinga
Exposures Product Safety
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company 
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine
Emergent BioSolutions stock jumped early Friday. 
Via Investor's Business Daily
Exposures Product Safety
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
From Emergent BioSolutions
Via GlobeNewswire
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
The FDA has approved Emergent BioSolutions' supplemental Biologics License Application for ACAM2000 to include the prevention of mpox disease in high-risk individuals, with the approval based on human... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.